See more : Reading International, Inc. (RDI) Income Statement Analysis – Financial Results
Complete financial analysis of Alzamend Neuro, Inc. (ALZN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alzamend Neuro, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wholehealth Products, Inc. (GWPC) Income Statement Analysis – Financial Results
- Entertainment Arts Research, Inc. (EARI) Income Statement Analysis – Financial Results
- Ascendis Health Limited (ASC.JO) Income Statement Analysis – Financial Results
- China Minsheng Banking Corp., Ltd. (CGMBF) Income Statement Analysis – Financial Results
- Techtronic Industries Company Limited (TTNDY) Income Statement Analysis – Financial Results
Alzamend Neuro, Inc. (ALZN)
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 50.74K | 23.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.74K | -23.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.46M | 7.45M | 5.20M | 1.31M | 1.07M | 3.70M | 323.40K | 275.05K | 0.00 |
| General & Administrative | 3.24M | 6.68M | 7.12M | 3.64M | 3.35M | 1.31M | 545.12K | 942.51K | 69.46K |
| Selling & Marketing | 247.33K | 742.60K | 17.65K | 0.00 | 0.00 | 0.00 | 29.91K | 330.84K | 0.00 |
| SG&A | 3.48M | 7.42M | 7.12M | 3.64M | 3.35M | 1.31M | 575.03K | 1.27M | 69.46K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.94M | 14.87M | 12.32M | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| Cost & Expenses | 9.94M | 14.87M | 12.32M | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| Interest Income | 0.00 | 7.70 | 46.52 | 1.71K | 13.93K | 146.39K | 33.23K | 21.50K | 0.00 |
| Interest Expense | 10.10K | 7.70K | 46.52K | 158.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.74K | 23.07K | 3.55K | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| EBITDA | -9.89M | -14.85M | -12.32M | 0.00 | 0.00 | 0.00 | 7.34K | -21.50K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.94M | -14.87M | -12.32M | -4.95M | -4.42M | -5.01M | -898.43K | -1.55M | -69.46K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.10K | -7.70K | -42.52K | -94.68K | 13.93K | 146.39K | -33.23K | -21.50K | 0.00 |
| Income Before Tax | -9.95M | -14.88M | -12.36M | -5.05M | -4.41M | -4.86M | -931.66K | -1.57M | -69.46K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -144.83K | 42.52K | 157.10K | -13.93K | -146.39K | -898.43K | -21.50K | 0.00 |
| Net Income | -9.95M | -14.88M | -12.40M | -5.20M | -4.40M | -4.86M | -931.66K | -1.57M | -69.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.72 | -22.89 | -20.92 | -10.75 | -9.26 | -12.40 | -1.64 | -8.18 | -0.42 |
| EPS Diluted | -14.70 | -22.89 | -20.88 | -10.74 | -9.25 | -12.40 | -1.64 | -8.18 | -0.42 |
| Weighted Avg Shares Out | 676.00K | 650.00K | 593.00K | 484.00K | 475.00K | 392.00K | 568.70K | 192.00K | 165.00K |
| Weighted Avg Shares Out (Dil) | 676.57K | 650.13K | 593.97K | 484.33K | 475.02K | 392.29K | 568.70K | 192.01K | 165.30K |
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details
Monday, Alzamend Neuro Inc. ALZN stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization.
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
ATLANTA--(BUSINESS WIRE)---- $ALZN #10_day_termination_process_started--Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program.
PRISM MarketView – Weekly Market Report – April 26, 2024
PRISM Market Pulse: Equities Rally Amid Mixed Big Tech Earnings; Economic Shifts and Sector-Specific Highlights New York, N.Y., April 26, 2024 – PRISM MarketView – Equities were higher through the morning into midday trading as the S&P 500 and Nasdaq are...
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement
ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement.
Alzamend Neuro Announces Reverse Stock Split
ATLANTA--(BUSINESS WIRE)---- $ALZN #15_to_1_stock_reversal--Alzamend Neuro Announces Reverse Stock Split.
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech stocks that have 10X potential, or better.
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it's not particularly likely to happen.
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
LAS VEGAS--(BUSINESS WIRE)--Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“Ault Alliance” or the “Company”), is proud to announce that Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”) has initiated its Phase I/IIA clinical trial for its immunotherapeutic vaccine (ALZN002)...
Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the initiation of...
Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced the completion of...
Source: https://incomestatements.info
Category: Stock Reports